XORTX Therapeutics
XRTX
3 hedge funds and large institutions have $26.6K invested in XORTX Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
20% less capital invested
Capital invested by funds: $33.2K → $26.6K (-$6.61K)
40% less funds holding
Funds holding: 5 → 3 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$11.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.1K |
| 3 |
VF
Virtu Financial
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $18.3K | +$19K | +69 | New |
|
2
Osaic Holdings
Scottsdale,
Arizona
| $6.74K | – | – | – |
|
|
CA
3
Clearstead Advisors
Cleveland,
Ohio
| $1.62K | – | – | – |
|
4
Bank of America
Charlotte,
North Carolina
| $1 | – | – | – |
|
|
TSS
5
Two Sigma Securities
New York
| – | -$11.2K | -59 | Closed |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$10.1K | -53 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$6K | -32 | Closed |
|
XRTX Hedge Fund Activity: Q2 2023 in Review
3 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q2 2023, worth a combined $26.6K — down 20% from $33.2K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of XRTX and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $19K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $11.2K sold.
- 3 institutional investors held XORTX Therapeutics (XRTX) as of Q2 2023, down from 5 in Q1 2023.
- Funds reported $26.6K of XORTX Therapeutics stock for Q2 2023, down 20% quarter-over-quarter.
- 1 fund opened new XORTX Therapeutics positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest XORTX Therapeutics buyer in Q2 2023 was Citadel Advisors, an estimated $19K added.
- The largest XORTX Therapeutics seller in Q2 2023 was Two Sigma Securities, an estimated $11.2K sold.
Based on aggregated 13F filings for Q2 2023.